Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 164,183 |
|
|||||
| News | - | ||||||
| Day High | 8.11 | Low High |
|||||
| Day Low | 7.43 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Larimar Therapeutics Inc | LRMR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.68 | 9.29% | 8.00 | 13:17:52 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 7.43 | 7.43 | 8.11 | 7.32 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,526 | 164,183 | $ 7.94 | $ 1,303,068 | - | 2.18 - 13.68 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:17:57 | 1 | $ 7.9837 | USD |
Larimar Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 63.16M | 63.80M | - | 0 | -36.95M | -0.58 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Larimar Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical LRMR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 8.21 | 8.295 | 7.04 | 7.58 | 229,249 | -0.21 | -2.56% |
| 1 Month | 7.22 | 8.33 | 5.91 | 7.05 | 285,352 | 0.78 | 10.80% |
| 3 Months | 12.92 | 13.07 | 5.91 | 8.74 | 447,991 | -4.92 | -38.08% |
| 6 Months | 2.40 | 13.68 | 2.40 | 8.69 | 408,313 | 5.60 | 233.33% |
| 1 Year | 4.03 | 13.68 | 2.18 | 6.80 | 323,542 | 3.97 | 98.51% |
| 3 Years | 11.62 | 15.49 | 1.53 | 6.13 | 209,405 | -3.62 | -31.15% |
| 5 Years | 12.00 | 25.87 | 1.53 | 6.93 | 172,033 | -4.00 | -33.33% |
Larimar Therapeutics Description
| Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. |
